About: Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists
Creator	Drph, Ibrahim, Said Gibofsky, Allan Goodman, Susan Jannat-Khah, Deanna Mehta, Bella Moezinia, Carine Pearce-Fisher, Diyu Salmon, Jane Tornberg, Haley
Source	Medline; PMC
abstract	With hydroxychloroquine (HCQ) and chloroquine (CQ) emerging as potential therapies for coronavirus disease 2019 (COVID-19), shortages have been reported. We aimed to understand how rheumatologists, one of the most common prescribers of HCQ/CQ, prescribed these medications to manage COVID-19 and to understand if their patients are affected by shortages. METHODS: Between April 8 and April 27, 2020, an online survey was distributed to a convenience sample of rheumatologists who practice medicine in a diverse range of settings globally, resulting in 506 responses. Adjusted Poisson regression models were calculated. RESULTS: Only 6% of respondents prescribed HCQ/CQ for COVID-19 prophylaxis, and only 12% for outpatient treatment of COVID-19. Compared to the United States, the likelihood of prescribing HCQ/CQ for prophylaxis was higher in India (adjusted risk ratio [aRR], 6.7; 95% confidence interval [CI], 2.7–16.8; p < 0.001). Further, compared to the United States and those with 1 to 5 years of experience, rheumatologists in Europe (aRR, 2.9; 95% CI, 1.6–5.3; p < 0.001) and those with 10+ years of experience (11–20 years: aRR, 2.5; 95% CI, 1.2–5.3; p = 0.015; 21+ years: aRR = 3.3; 95% CI, 1.4–7.4; p = 0.004) had a higher likelihood of prescribing HCQ/CQ for outpatient treatment. Of note, 71% of all rheumatologists reported that their patients were directly affected by HCQ/CQ shortages. CONCLUSION: The results suggest that only a small percentage of rheumatologists are prescribing HCQ/CQ for prophylaxis or outpatient treatment of COVID-19. Medication shortages experienced by large numbers of autoimmune disease patients are concerning and should play a role in decisions, especially given poor efficacy data for HCQ/CQ in COVID-19.
has issue date	2020-07-16(xsd:dateTime)
bibo:doi	10.1097/rhu.0000000000001539
bibo:pmid	32694358
has license	no-cc
sha1sum (hex)	d9b1af3f9c960ffab27250c7de95c33cca78bcfc
schema:url	https://doi.org/10.1097/rhu.0000000000001539
resource representing a document's title	Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists
has PubMed Central identifier	PMC7437433
has PubMed identifier	32694358
schema:publication	J Clin Rheumatol
resource representing a document's body	covid:d9b1af3f9c960ffab27250c7de95c33cca78bcfc#body_text
is schema:about of	named entity 'coronavirus disease 2019' named entity 'hydroxychloroquine' named entity 'REPORTED' covid:arg/d9b1af3f9c960ffab27250c7de95c33cca78bcfc named entity 'rheumatologists' named entity 'Chloroquine' named entity 'HCQ' named entity 'Europe' named entity 'Europe' named entity 'COVID-19' named entity 'HCQ' named entity 'Ultrasound' named entity 'rheumatologists' named entity 'randomized clinical trial' named entity 'primary care physicians' named entity 'rheumatologists' named entity 'Hospital for Special Surgery' named entity 'WhatsApp' named entity 'Demographic' named entity 'rheumatologists' named entity 'HCQ' named entity 'HCQ' named entity 'Emergency Use Authorization' named entity 'convenience sample' named entity 'cardiac toxicity' named entity 'Rheumatologists' named entity 'rheumatologists' named entity 'India' named entity 'disease control' named entity 'HCQ' named entity 'rheumatologists' named entity 'rheumatologists' named entity 'rheumatologists' named entity 'Hydroxychloroquine' named entity 'rheumatologists' named entity '16.8' named entity 'HCQ' named entity 'COVID' named entity 'toxicity' named entity 'COVID-19' named entity 'rheumatologists' named entity 'Stata' named entity 'pediatric' named entity 'United States' named entity 'COVID' named entity 'autoimmune' named entity 'rheumatologists' named entity '2019-nCoV' named entity 'COVID' named entity 'COVID' named entity 'England' named entity 'prescribers' named entity 'United States' named entity '95% CI' named entity 'hydroxychloroquine' named entity 'rheumatologists' named entity 'Indian Rheumatology Association' named entity 'COVID' named entity 'prophylaxis' named entity 'chloroquine' named entity 'HCQ' named entity 'rheumatologists' named entity 'COVID' named entity 'social media platforms' named entity 'United States' named entity 'lupus' named entity 'Emergency Use Authorization' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'chloroquine' named entity 'coronavirus' named entity 'hydroxychloroquine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software